Vor Biopharma Inc. - Common Stock (VOR)

Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Vor shares are higher lower on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing.

Vor Biopharma reveals promising Phase 1/2 study results for AML treatment, and it is planning FDA pivotal trial discussions.

VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the second quarter of 2024.

VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the first quarter of 2024.

Although speculation can be bad for your blood pressure, these compelling penny stocks have some strong endorsements.

VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the fourth quarter of 2023.

  On Tuesday, 647 companies set new 52-week lows.

  On Thursday, 128 companies set new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

  During Tuesday's session, 275 companies made new 52-week lows.

  During the Friday's sesion, 157 stocks hit new 52-week lows.